1. Home
  2. SLNO vs AB Comparison

SLNO vs AB Comparison

Compare SLNO & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • AB
  • Stock Information
  • Founded
  • SLNO 1999
  • AB 1987
  • Country
  • SLNO United States
  • AB United States
  • Employees
  • SLNO N/A
  • AB N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • AB Investment Managers
  • Sector
  • SLNO Health Care
  • AB Finance
  • Exchange
  • SLNO Nasdaq
  • AB Nasdaq
  • Market Cap
  • SLNO 3.8B
  • AB 4.5B
  • IPO Year
  • SLNO 2014
  • AB 1988
  • Fundamental
  • Price
  • SLNO $62.37
  • AB $38.32
  • Analyst Decision
  • SLNO Strong Buy
  • AB Hold
  • Analyst Count
  • SLNO 9
  • AB 5
  • Target Price
  • SLNO $116.78
  • AB $40.40
  • AVG Volume (30 Days)
  • SLNO 2.7M
  • AB 150.1K
  • Earning Date
  • SLNO 11-05-2025
  • AB 10-23-2025
  • Dividend Yield
  • SLNO N/A
  • AB 8.48%
  • EPS Growth
  • SLNO N/A
  • AB 17.05
  • EPS
  • SLNO N/A
  • AB 3.37
  • Revenue
  • SLNO $32,656,999.00
  • AB N/A
  • Revenue This Year
  • SLNO N/A
  • AB N/A
  • Revenue Next Year
  • SLNO $181.85
  • AB $7.35
  • P/E Ratio
  • SLNO N/A
  • AB $11.42
  • Revenue Growth
  • SLNO N/A
  • AB N/A
  • 52 Week Low
  • SLNO $41.50
  • AB $32.28
  • 52 Week High
  • SLNO $90.32
  • AB $43.30
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 48.83
  • AB 48.56
  • Support Level
  • SLNO $55.78
  • AB $37.25
  • Resistance Level
  • SLNO $68.46
  • AB $38.90
  • Average True Range (ATR)
  • SLNO 4.12
  • AB 0.63
  • MACD
  • SLNO 0.71
  • AB 0.10
  • Stochastic Oscillator
  • SLNO 67.58
  • AB 59.79

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About AB AllianceBernstein Holding L.P.

AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.

Share on Social Networks: